Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2

U Schubert, DE Ott, EN Chertova… - Proceedings of the …, 2000 - National Acad Sciences
U Schubert, DE Ott, EN Chertova, R Welker, U Tessmer, MF Princiotta, JR Bennink…
Proceedings of the National Academy of Sciences, 2000National Acad Sciences
Retrovirus assembly and maturation involve folding and transport of viral proteins to the
virus assembly site followed by subsequent proteolytic cleavage of the Gag polyprotein
within the nascent virion. We report that inhibiting proteasomes severely decreases the
budding, maturation, and infectivity of HIV. Although processing of the Env glycoproteins is
not changed, proteasome inhibitors inhibit processing of Gag polyprotein by the viral
protease without affecting the activity of the HIV-1 viral protease itself, as demonstrated by in …
Retrovirus assembly and maturation involve folding and transport of viral proteins to the virus assembly site followed by subsequent proteolytic cleavage of the Gag polyprotein within the nascent virion. We report that inhibiting proteasomes severely decreases the budding, maturation, and infectivity of HIV. Although processing of the Env glycoproteins is not changed, proteasome inhibitors inhibit processing of Gag polyprotein by the viral protease without affecting the activity of the HIV-1 viral protease itself, as demonstrated by in vitro processing of HIV-1 Gag polyprotein Pr55. Furthermore, this effect occurs independently of the virus release function of the HIV-1 accessory protein Vpu and is not limited to HIV-1, as proteasome inhibitors also reduce virus release and Gag processing of HIV-2. Electron microscopy analysis revealed ultrastructural changes in budding virions similar to mutants in the late assembly domain of p6gag, a C-terminal domain of Pr55 required for efficient virus maturation and release. Proteasome inhibition reduced the level of free ubiquitin in HIV-1-infected cells and prevented monoubiquitination of p6gag. Consistent with this, viruses with mutations in PR or p6gag were resistant to detrimental effects mediated by proteasome inhibitors. These results indicate the requirement for an active proteasome/ubiquitin system in release and maturation of infectious HIV particles and provide a potential pharmaceutical strategy for interfering with retrovirus replication.
National Acad Sciences